Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

SCN1A variations and response to multiple antiepileptic drugs

The Pharmacogenomics Journal volume 14, pages 385–389 (2014)Cite this article

Subjects

Abstract

In the current study, we have used the haplotype-tagging single-nucleotide polymorphisms (SNPs) to determine associations between genetic variants in SCN1A and treatment response in 519 Caucasian patients with known response status for epilepsy treated with antiepileptic drugs (AEDs) with sodium channel blocking effects. Nine SNPs within SCN1A were genotyped in this cohort. The only association observed was for rs10188577. A greater proportion of drug-resistant patients were heterozygous compared with drug responsive patients (48.3% vs 35.4%, P=0.014). After correction for potential confounding factors, the association for rs10188577 was only marginally significant (P=0.049). In light of our findings, it seems unlikely that rs10188577 could be a major determinant of response to AEDs. However, looking at the influence of rs10188577 on the expressed quantitative trait association patterns within the immediate vicinity of SCN1A, we found significant associations with neighbouring sodium channel genes, SCN7A and SCN9A (P<0.025), which warrants further studies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. World Health Organization. Atlas: epilepsy care in the world. World Health Organization: Geneva, 2005, Available at http://www.who.int/mental_health/neurology/epilepsy_atlas_introdion.pdf . Accessed on July 2013.

  2. Walley N, Sisodiya SM, Goldstein DB . Pharmacogenetics and pharmacogenomics. In:Engel J Jr, Pedley TA (eds). Epilepsy: A Comprehensive Textbook 2nd edn. Lippincott Williams & Wilkins: Philadelphia, 2008.

    Google Scholar 

  3. Loescher W, Klotz U, Zimprich F, Schmidt D . The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009; 50: 1–23.

    Article  CAS  Google Scholar 

  4. Depondt C . Pharmacogenetics in epilepsy treatment: sense or nonsense? Pers Med 2008; 5: 123–131.

    Article  CAS  Google Scholar 

  5. Hollingworth SA, Eadie MJ . Antiepileptic drugs in Australia: 2002-2007. Pharmacoepidemiol Drug Saf 2010; 19: 82–89.

    Article  Google Scholar 

  6. Zuliani V, Fantini M, Rivara M . Sodium channel blockers as therapeutic target for treating epilepsy: recent updates. Curr Top Med Chem 2012; 12: 962–970.

    Article  CAS  Google Scholar 

  7. Porter RJ . Addressing the need for new therapies for epilepsy. Epilepsia 2012; 53: 1840–1841.

    Article  Google Scholar 

  8. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci USA 2005; 102: 5507–5512.

    Article  CAS  Google Scholar 

  9. Heinzen EL, Yoon W, Tate SK, Sen A, Wood NW, Sisodiya SM et al. Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am J Hum Genet 2007; 80: 876–883.

    Article  CAS  Google Scholar 

  10. Hung CC, Huang HC, Gao YH, Chang WL, Ho JL, Chiou MH et al. Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients. Pharmacogenomics 2012; 13: 1339–1349.

    Article  CAS  Google Scholar 

  11. Manna I, Gambardella A, Bianchi A, Striano P, Tozzi R, Aguglia U et al. A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia 2011; 52: e40–e44.

    Article  Google Scholar 

  12. Zimprich F, Stogmann E, Bonelli S, Baumgartner C, Mueller JC, Meitinger T et al. A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy. Epilepsia 2008; 49: 1108–1109.

    Article  Google Scholar 

  13. Tate SK, Singh R, Hung CC, Tai JJ, Depondt C, Cavalleri GL et al. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet Genomics 2006; 16: 721–726.

    Article  CAS  Google Scholar 

  14. Haerian BS, Baum L, Tan HJ, Kwan P, Raymond AA, Saruwatari J et al. SCN1A IVS5N+5 polymorphism and response to sodium valproate: a multicenter study. Pharmacogenomics 2012; 13: 1477–1485.

    Article  CAS  Google Scholar 

  15. Depondt C, Godard P, Espel RS, Da Cruz AL, Lienard P, Pandolfo M . A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol 2011; 18: 1159–1164.

    Article  CAS  Google Scholar 

  16. Sánchez MB, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizan EM et al. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure 2010; 19: 93–101.

    Article  Google Scholar 

  17. Lakhan R, Kumari R, Misra UK, Kalita J, Pradhan S, Mittal B . Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. Br J Clin Pharmacol 2009; 68: 214–220.

    Article  CAS  Google Scholar 

  18. Jang SY, Kim MK, Lee KR, Park MS, Kim BC, Cho KH et al. Gene-to-gene interaction between sodium channel-related genes in determining the risk of antiepileptic drug resistance. J Korean Med Sci 2009; 24: 62–68.

    Article  CAS  Google Scholar 

  19. Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K . Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Bri J Clin Pharmacol 2008; 66: 304–307.

    Article  CAS  Google Scholar 

  20. Kwan P, Poon WS, Ng HK, Kang DE, Wong V, Ng PW et al. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics 2008; 18: 989–998.

    Article  CAS  Google Scholar 

  21. Tan NCK, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears DF et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 2004; 63: 1090–1092.

    Article  CAS  Google Scholar 

  22. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W et al. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on classification and terminology, 2005-2009. Epilepsia 2010; 51: 676–685.

    Article  Google Scholar 

  23. Mulley JC, Scheffer IE, Petrou S, Dibbens LM, Berkovic SF, Harkin LA . SCN1A mutations and epilepsy. Hum Mutat 2005; 25: 535–534.

    Article  CAS  Google Scholar 

  24. Barrett JC, Fry B, Maller J, Daly MJ . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263–265.

    Article  CAS  Google Scholar 

  25. Nyholt D . A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765–769.

    Article  CAS  Google Scholar 

  26. Skol AD, Scott LJ, Abecasis GR, Boehnke M . Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 2006; 38: 209–213.

    Article  CAS  Google Scholar 

  27. Yang TP, Beazley C, Montgomery SB, Dimas AS, Gutierrez-Arcelus M, Stranger BE et al. Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics 2010; 26: 2474–2476.

    Article  CAS  Google Scholar 

  28. Stranger BE, Montgomery SB, Dimas AS, Parts L, Stegle O, Ingle CE et al. Patterns of cis regulatory variation in diverse human populations. PLoS Genet 2012; 8: e1002639.

    Article  CAS  Google Scholar 

  29. Treatment of Epilepsy. Therapeutic Guidelines Ltd. eTG Complete, 2013. North Melbourne: Therapeutic Guidelines Ltd. Available from http://www.tg.org.au/.

  30. Treatment of Epilepsy, Rossi S (ed). Australian Medicines Handbook [AMH]. S. Aust: Australian Medicines Handbook Pty Ltd: Adelaide; 2013.

  31. Cockerell OC, Johnson AL, Sander JW, Shorvon SD . Prognosis of epilepsy: a review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study. Epilepsia 1997; 38: 31–46.

    Article  CAS  Google Scholar 

  32. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA . Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007; 62: 382–389.

    Article  Google Scholar 

  33. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B et al. Defining early seizure outcomes in pediatric epilepsy: the good, the bad and the in-between. Epilepsy Res 2001; 43: 75–84.

    Article  CAS  Google Scholar 

  34. Semah F, Picot MC, Adam C, Broglin D, Arzimanoglou A, Bazin B et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998; 51: 1256–1262.

    Article  CAS  Google Scholar 

  35. Zhang C, Wong V, Ng PW, Lui CH, Sin NC, Wong KS et al. Failure to detect association between polymorphisms of the sodium channel gene SCN1A and febrile seizures in Chinese patients with epilepsy. Epilepsia 2010; 51: 1878–1881.

    Article  CAS  Google Scholar 

  36. Oterino A, Castillo J, Cayon A, Toriello M, Alonso A, Ruiz-Alegria C et al. Is the FHM3 gene SCN1A implicated in migraine? Cephalalgia 2007; 27: S577.

    Article  Google Scholar 

Download references

Acknowledgements

VS, COD and LMD were supported by Division Research Development Grants Scheme from the University of South Australia.

Author information

Authors and Affiliations

  1. School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia

    T S C Yip, C O'Doherty, L M Dibbens & V Suppiah

  2. Department of Neurology, National Neuroscience Institute, Singapore

    N C K Tan

Authors
  1. T S C Yip
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C O'Doherty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N C K Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L M Dibbens
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V Suppiah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V Suppiah.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yip, T., O'Doherty, C., Tan, N. et al. SCN1A variations and response to multiple antiepileptic drugs. Pharmacogenomics J 14, 385–389 (2014). https://doi.org/10.1038/tpj.2013.43

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2013.43

Keywords

This article is cited by

Search

Advanced search

Quick links